Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $6.63.

A number of equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group raised their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th.

Institutional Trading of Taysha Gene Therapies

Several large investors have recently bought and sold shares of the business. Creative Planning acquired a new position in Taysha Gene Therapies during the third quarter worth about $28,000. Principal Financial Group Inc. acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after purchasing an additional 17,446 shares during the last quarter. Intech Investment Management LLC acquired a new position in Taysha Gene Therapies during the 3rd quarter worth approximately $85,000. Finally, Scientech Research LLC bought a new position in Taysha Gene Therapies in the 2nd quarter valued at approximately $97,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Stock Up 8.0 %

TSHA stock opened at $3.24 on Friday. Taysha Gene Therapies has a fifty-two week low of $1.19 and a fifty-two week high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock has a market capitalization of $664.01 million, a price-to-earnings ratio of 5.14 and a beta of 0.44. The business’s fifty day moving average price is $2.06 and its two-hundred day moving average price is $2.39.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.